Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head and Neck Cancer—Pilot Results from RTOG 0522

Documenti analoghi

• Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
  di: Ang, K. Kian, et al.
  Pubblicazione: (2014)
• Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
  di: Machtay, Mitchell, et al.
  Pubblicazione: (2008)
• Quality of life and performance status from a sub-study conducted within a prospective phase III randomized trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced head and neck carcinoma: NRG Oncology RTOG 0522
  di: Truong, Minh Tam, et al.
  Pubblicazione: (2016)
• Risk Groups of Laryngeal Cancer Treated with Chemoradiation According to Nomogram Scores – A Pooled Analysis of RTOG 0129 and 0522
  di: Awan, Musaddiq J., et al.
  Pubblicazione: (2021)
• Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel and Cisplatin With Radiation Therapy for Patients With Resected High-Risk Head and Neck Squamous Cell Carcinoma: Report of the Phase II Trial RTOG 0024
  di: Rosenthal, David I., et al.
  Pubblicazione: (2009)